Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Edwards Finds Transcatheter Valve Adoption In U.S. Slower Than Expected

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences is lowering its revenue expectations for 2013 based on adoption rates so far of its transcatheter aortic valve implant technology.

You may also be interested in...



Edwards Reports TAVR Sales Progress In U.S. And Abroad

Edwards Lifesciences reported 19 percent year-over-year growth in worldwide sales of its Sapien transcatheter aortic valve systems during the second quarter of 2014. The company cites the ongoing launch of the Sapien 3 system in Europe and Sapien XT in the U.S. as keys to continuing growth.

Edwards Plans To Keep ‘First-Mover’ Advantage In TAVI Against Emerging Competition

Edwards is counting on the Sapien XT valve, which will likely earn FDA approval soon, to compete with Medtronic’s recently approved CoreValve in the U.S, while in Europe the company is working quickly to upgrade customers to Sapien 3.

Medtronic CoreValve Meets Targets In Extreme-Risk Group; Panel Will Not Be Needed, FDA Says

The firm now expects to gain approval for the extreme-risk indication of its transcatheter aortic heart valve months earlier than earlier predicted following well-received pivotal trial data reported last week at the Transcatheter Cardiovascular Therapeutics meeting.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT031995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel